Large Outflow of Money Witnessed in Amgen Inc.

Amgen Inc. (AMGN) traded higher in the last at $159.67, gaining 2.99 points or 1.91%. From the data available, it can be said that the stock did not make an impact in the money flow department with the net figure coming to be $(-10.43) million. The composite uptick value of $127.61 million was eclipsed by the accrued downtick value of $138.03 million, thereby ensuring the up/down ratio of 0.92. For the week, the shares have posted returns of 1.6%.A block trade registered during the day has revealed $1.59 million in upticks and $12.51 million in downticks. The up/down ratio in this case turned out to be 0.13. The net money flow for the block trade was $(-10.93) million.Block trades are executed by Investment Banking firms or Wealth Managers shifting positions or Day traders taking advantage of trading signals.

Shares of Amgen Inc. rose by 3.61% in the last five trading days and 9.21% for the last 4 weeks. Amgen Inc. is up 13.88% in the last 3-month period. Year-to-Date the stock performance stands at 9.21%. Amgen Inc. (NASDAQ:AMGN) rose 1.91% or 2.99 points on Wednesday and made its way into the gainers of the day. After trading began at $158.59 the stock was seen hitting $159.75 as a peak level and $157.05 as the lowest level. The stock ended up at $159.67. The daily volume was measured at 3,924,817 shares. The 52-week high of the share price is $176.85 and the 52-week low is $133.64. The company has a market cap of $118,782 million.

Company has reported several Insider transactions to the SEC, on Aug 3, 2016, Annette Louise Such (VP, Finance and CAO) sold 3,000 shares at 174.59 per share price.On May 5, 2016, Madhavan Balachandran (EVP, Operations) sold 30,000 shares at 154.12 per share price.On May 3, 2016, Sean E Harper (EVP, Research & Development) sold 21,875 shares at 157.99 per share price.

Amgen Last issued its quarterly earnings results on Oct 27, 2016. The company reported $3.02 EPS for the quarter, beating the analyst consensus estimate by $ 0.23. Analyst had a consensus of $2.79. The company had revenue of $5811.00 million for the quarter, compared to analysts expectations of $5702.65 million. The companys revenue was up 1.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.72 EPS.

Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Amgen was Upgraded by BofA/Merrill to Buy on Feb 1, 2017. Amgen was Downgraded by Credit Suisse to Neutral on Dec 20, 2016. Amgen was Initiated by Oppenheimer to Outperform on Dec 13, 2016. Amgen was Initiated by Mizuho on Nov 8, 2016 to Buy, Price Target of the shares are set at $164.

Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new sciences promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve peoples lives.

Amgen

Share this post

Leave a Reply